Circulating betatrophin is elevated in patients with type 1 and type 2 diabetes.

There is evidence that betatrophin, a hormone derived from adipose tissue and liver, affects the proliferation of pancreatic beta cells in mice. The aim of this study was to examine circulating betatrophin concentrations in Japanese healthy controls and patients with type 1 and type 2 diabetes. A total of 76 subjects (12 healthy controls, 34 type 1 diabetes, 30 type 2 diabetes) were enrolled in the study. Circulating betatrophin was measured with an ELISA kit and clinical parameters related to betatrophin were analyzed statistically. Circulating betatrophin (Log transformed) was significantly increased in patients with diabetes compared with healthy subjects (healthy controls, 2.29 ± 0.51; type 1 diabetes, 2.94 ± 0.44; type 2 diabetes, 3.17 ± 0.18; p<0.001, 4.1 to 5.4 times in pg/mL order). Age, HbA1c, fasting plasma glucose and Log triglyceride were strongly associated with Log betatrophin in all subjects (n=76) in correlation analysis. In type 1 diabetes, there was a correlation between Log betatrophin and Log CPR. These results provide the first evidence that circulating betatrophin is significantly elevated in Japanese patients with diabetes. The findings of this pilot study also suggest a possibility of association between the level of betatrophin and the levels of glucose and triglycerides.

[1]  J. Oller,et al.  Consensus and controversy , 1984 .

[2]  Kenichi Yoshida,et al.  ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase* , 2002, The Journal of Biological Chemistry.

[3]  Yosuke Ando,et al.  Angptl 3-null Mice Show Low Plasma Lipid Concentrations by Enhanced Lipoprotein Lipase Activity , 2006 .

[4]  Yosuke Ando,et al.  Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. , 2006, Experimental animals.

[5]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[7]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[8]  Jonathan C. Cohen,et al.  Atypical angiopoietin-like protein that regulates ANGPTL3 , 2012, Proceedings of the National Academy of Sciences.

[9]  Ren Zhang,et al.  Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. , 2012, Biochemical and biophysical research communications.

[10]  Jonathan C. Cohen,et al.  Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis , 2013, Proceedings of the National Academy of Sciences.

[11]  D. Melton,et al.  RETRACTED: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation , 2013, Cell.

[12]  P. Serup,et al.  Bulking up on beta cells. , 2013, The New England journal of medicine.

[13]  A. Abou-Samra,et al.  Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. , 2013, Biochemical and biophysical research communications.

[14]  P. Carlsson,et al.  Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes , 2013, Diabetologia.

[15]  A. Abou-Samra,et al.  Emerging roles of Lipasin as a critical lipid regulator. , 2013, Biochemical and Biophysical Research Communications - BBRC.

[16]  Jonathan C. Cohen,et al.  ANGPTL8/Betatrophin Does Not Control Pancreatic Beta Cell Expansion , 2014, Cell.

[17]  M. Martinell,et al.  Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes , 2014, International journal of endocrinology.

[18]  Jennifer G. Robinson,et al.  Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. , 2014, American journal of human genetics.

[19]  G. Frühbeck,et al.  Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. , 2014, The Journal of clinical endocrinology and metabolism.

[20]  Libin Zhou,et al.  Increased Circulating Levels of Betatrophin in Newly Diagnosed Type 2 Diabetic Patients , 2014, Diabetes Care.

[21]  A. Abou-Samra,et al.  A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy , 2014, Cardiovascular Diabetology.

[22]  A. Abou-Samra,et al.  An explanation for recent discrepancies in levels of human circulating betatrophin , 2014, Diabetologia.

[23]  A. Kautzky-Willer,et al.  Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals , 2014, Diabetologia.

[24]  B. Seyoum,et al.  Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity , 2014, Scientific Reports.

[25]  B. Wagner,et al.  Targeting the pancreatic β-cell to treat diabetes , 2014, Nature Reviews Drug Discovery.

[26]  K. Kaestner,et al.  Elevated Mouse Hepatic Betatrophin Expression Does Not Increase Human β-Cell Replication in the Transplant Setting , 2014, Diabetes.